Comprehensive support from technology validation to market entry
[by Ji, Yong Jun] Daewon Pharmaceutical announced on August 28 that it had convened a signing ceremony with Seoul Biohub at the Seoul Biohub Global Center to formalize the launch of the ‘2025 Seoul Biohub-Daewon Pharmaceutical Open Innovation Program.’
The second installment of this program is intended to identify promising startups engaged in next-generation novel drug development and to offer comprehensive support, ranging from advanced technological validation to facilitation of market entry.
In partnership with 강원 랜드 바카라 Biohub, Daewon Pharmaceutical conducted the recruitment process for participating companies between May and July of this year, culminating in the selection of Kytec Bio and Atomatrix.
Kytec Bio has developed the ‘FLIC’ platform, a novel conjugation technology that enables the attachment of anticancer drugs and other therapeutic agents to albumin. It minimizes structural modifications to albumin and provides cost savings over recombinant protein-based technologies. When applied in anticancer drug development, FLIC enhances the cellular uptake efficiency of FLIC-albumin drug conjugates by reducing the ability of cancer cells to discern whether the bound molecule is albumin.
Atomatrix is increasing the success rate of early-stage new drug candidate discovery through the world's first commercialized ‘membrane protein pharmacology signal prediction platform,’ which focuses on key therapeutic targets, including membrane proteins. In addition, the company is advancing its capabilities by developing technologies that leverage AI-driven modeling, molecular docking, and molecular dynamics simulations to predict novel drug candidates and drug-target binding affinities with target proteins.
Daewon 강원 랜드 바카라 intends to draw upon his extensive experience in 강원 랜드 바카라 development and industry-specific expertise to evaluate the commercialization potential of participating startups’ technologies and to deliver constructive feedback throughout the product development process. Startups demonstrating outstanding performance in the final assessment will be granted the opportunity to join Daewon 강원 랜드 바카라's flagship open innovation program, ‘The Ham Program.’
Under the agreement, 강원 랜드 바카라 Biohub will furnish essential infrastructure, including research facilities and shared equipment. Working in partnership with a professional accelerator (AC), the company will also deliver tailored support aligned with the specific needs of startups, encompassing corporate evaluations, technology and commercialization consulting, as well as validation activities in domestic and international markets.
"The open innovation program that we are promoting in partnership with the 강원 랜드 바카라 Biohub represents a vital platform for ensuring the future competitiveness of the pharmaceutical industry. Through collaboration with startups developing next-generation novel drug discovery technologies, we aim to generate innovative results together," expressed Lee Kyoung-june, Executive Director of Daewon Pharmaceutical Research Institute.
"Our partnership with Daewon Pharmaceutical is emerging as a model case of collaboration between the public and private sectors in fostering the growth of promising startups. We will continue to provide active support to these technologically advanced biotech ventures to help them achieve concrete and impactful outcomes," said Kim Hyun-woo, Director General of 강원 랜드 바카라 Biohub.